Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73


A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.

Aslostovar L, Boyd AL, Almakadi M, Collins TJ, Leong DP, Tirona RG, Kim RB, Julian JA, Xenocostas A, Leber B, Levine MN, Foley R, Bhatia M.

Blood Adv. 2018 Aug 14;2(15):1935-1945. doi: 10.1182/bloodadvances.2018015677.


Thyroid Hormones Are Transport Substrates and Transcriptional Regulators of Organic Anion Transporting Polypeptide 2B1.

Meyer Zu Schwabedissen HE, Ferreira C, Schaefer AM, Oufir M, Seibert I, Hamburger M, Tirona RG.

Mol Pharmacol. 2018 Jul;94(1):700-712. doi: 10.1124/mol.117.111161. Epub 2018 May 7.


Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease.

Tirona RG, Kassam Z, Strapp R, Ramu M, Zhu C, Liu M, Schwarz UI, Kim RB, Al-Judaibi B, Beaton MD.

Drug Metab Dispos. 2018 May;46(5):485-492. doi: 10.1124/dmd.117.079624. Epub 2018 Feb 22.


Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care.

Gulilat M, Tang A, Gryn SE, Leong-Sit P, Skanes AC, Alfonsi JE, Dresser GK, Henderson SL, Rose RV, Lizotte DJ, Teft WA, Schwarz UI, Tirona RG, Kim RB.

Can J Cardiol. 2017 Aug;33(8):1036-1043. doi: 10.1016/j.cjca.2017.04.008. Epub 2017 Apr 24.


Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas.

Kim M, Deacon P, Tirona RG, Kim RB, Pin CL, Meyer Zu Schwabedissen HE, Wang R, Schwarz UI.

Histochem Cell Biol. 2017 Oct;148(4):345-357. doi: 10.1007/s00418-017-1580-6. Epub 2017 May 10.


G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.

Blake A, Dragan M, Tirona RG, Hardy DB, Brackstone M, Tuck AB, Babwah AV, Bhattacharya M.

Sci Rep. 2017 Apr 19;7:46525. doi: 10.1038/srep46525.


CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease.

Wilson A, Tirona RG, Kim RB.

Inflamm Bowel Dis. 2017 May;23(5):804-813. doi: 10.1097/MIB.0000000000001062.


Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.

Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, Malhotra N, Beaton MD.

World J Gastroenterol. 2017 Jan 7;23(1):141-150. doi: 10.3748/wjg.v23.i1.141.


Disrupted Murine Gut-to-Human Liver Signaling Alters Bile Acid Homeostasis in Humanized Mouse Liver Models.

Chow EC, Quach HP, Zhang Y, Wang JZ, Evans DC, Li AP, Silva J, Tirona RG, Lai Y, Pang KS.

J Pharmacol Exp Ther. 2017 Jan;360(1):174-191. Epub 2016 Oct 27.


A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.

Woolsey SJ, Beaton MD, Mansell SE, Leon-Ponte M, Yu J, Pin CL, Adams PC, Kim RB, Tirona RG.

Mol Pharmacol. 2016 Oct;90(4):437-46. doi: 10.1124/mol.116.104687. Epub 2016 Aug 1.


Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.

Woolsey SJ, Beaton MD, Choi YH, Dresser GK, Gryn SE, Kim RB, Tirona RG.

Basic Clin Pharmacol Toxicol. 2016 Apr;118(4):284-91. doi: 10.1111/bcpt.12492. Epub 2015 Oct 14.


Erratum to: Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease.

Wilson A, Teft WA, Morse BL, Choi YH, Woolsey S, DeGorter MK, Hegele RA, Tirona RG, Kim RB.

Dig Dis Sci. 2016 Jan;61(1):325. doi: 10.1007/s10620-015-3826-2. No abstract available.


CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease.

Woolsey SJ, Mansell SE, Kim RB, Tirona RG, Beaton MD.

Drug Metab Dispos. 2015 Oct;43(10):1484-90. doi: 10.1124/dmd.115.065979. Epub 2015 Jul 31.


Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease.

Wilson A, Teft WA, Morse BL, Choi YH, Woolsey S, DeGorter MK, Hegele RA, Tirona RG, Kim RB.

Dig Dis Sci. 2015 Dec;60(12):3620-30. doi: 10.1007/s10620-015-3797-3. Epub 2015 Jul 10. Erratum in: Dig Dis Sci. 2016 Jan;61(1):325.


Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance.

Lee HH, Leake BF, Teft W, Tirona RG, Kim RB, Ho RH.

Mol Cancer Ther. 2015 Apr;14(4):994-1003. doi: 10.1158/1535-7163.MCT-14-0547. Epub 2015 Feb 18.


Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling.

Posada MM, Bacon JA, Schneck KB, Tirona RG, Kim RB, Higgins JW, Pak YA, Hall SD, Hillgren KM.

Drug Metab Dispos. 2015 Mar;43(3):325-34. doi: 10.1124/dmd.114.059618. Epub 2014 Dec 12.


The kinetics of cystatin C removal by hemodialysis.

Huang SH, Tirona RG, Reid-Wilkinson F, Thomson BK, Filler G, Stodilka R, Lindsay RM.

Am J Kidney Dis. 2015 Jan;65(1):174-5. doi: 10.1053/j.ajkd.2014.08.010. Epub 2014 Oct 3. No abstract available.


Genotype-guided dosing of vitamin K antagonists.

Schwarz UI, Kim RB, Tirona RG.

N Engl J Med. 2014 May 1;370(18):1761-2. doi: 10.1056/NEJMc1402521. No abstract available.


Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy.

Ziada A, Schwarz UI, DeGorter MK, Tirona RG, Ban MR, Kim RB, Hegele RA.

Can J Cardiol. 2013 Nov;29(11):1395-9. doi: 10.1016/j.cjca.2013.08.003.


Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.

Bojic LA, Burke AC, Chhoker SS, Telford DE, Sutherland BG, Edwards JY, Sawyez CG, Tirona RG, Yin H, Pickering JG, Huff MW.

Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):52-60. doi: 10.1161/ATVBAHA.113.301830. Epub 2013 Oct 24.


Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.

DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, Myers K, Zou G, Iwuchukwu O, Wei WQ, Wilke RA, Hegele RA, Kim RB.

Circ Cardiovasc Genet. 2013 Aug;6(4):400-8. doi: 10.1161/CIRCGENETICS.113.000099. Epub 2013 Jul 22.


Ciprofloxacin and rifampin have opposite effects on levothyroxine absorption.

Goldberg AS, Tirona RG, Asher LJ, Kim RB, Van Uum SH.

Thyroid. 2013 Nov;23(11):1374-8. doi: 10.1089/thy.2013.0014. Epub 2013 Oct 16.


CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.

Teft WA, Gong IY, Dingle B, Potvin K, Younus J, Vandenberg TA, Brackstone M, Perera FE, Choi YH, Zou G, Legan RM, Tirona RG, Kim RB.

Breast Cancer Res Treat. 2013 May;139(1):95-105. doi: 10.1007/s10549-013-2511-4. Epub 2013 Apr 12. Erratum in: Breast Cancer Res Treat. 2013 Nov;142(1):225.


Transport function and transcriptional regulation of a liver-enriched human organic anion transporting polypeptide 2B1 transcriptional start site variant.

Knauer MJ, Girdwood AJ, Kim RB, Tirona RG.

Mol Pharmacol. 2013 Jun;83(6):1218-28. doi: 10.1124/mol.112.083618. Epub 2013 Mar 26.


Case report: atenolol overdose successfully treated with hemodialysis.

Huang SH, Tirona RG, Ross C, Suri RS.

Hemodial Int. 2013 Oct;17(4):652-5. doi: 10.1111/hdi.12020. Epub 2013 Jan 24.


Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.

Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, DeGorter MK, Woolsey S, Tirona RG, Kim RB.

Eur Heart J. 2012 Nov;33(22):2856-2464a. doi: 10.1093/eurheartj/ehs042. Epub 2012 Feb 27.


Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity.

DeGorter MK, Ho RH, Leake BF, Tirona RG, Kim RB.

Mol Pharm. 2012 Apr 2;9(4):986-95. doi: 10.1021/mp200629s. Epub 2012 Mar 6.


Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects.

DeGorter MK, Urquhart BL, Gradhand U, Tirona RG, Kim RB.

J Clin Pharmacol. 2012 Nov;52(11):1689-97. doi: 10.1177/0091270011422815. Epub 2011 Dec 13.


Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.

Gong IY, Schwarz UI, Crown N, Dresser GK, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Wells PS, Kim RB, Tirona RG.

PLoS One. 2011;6(11):e27808. doi: 10.1371/journal.pone.0027808. Epub 2011 Nov 16.


Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study.

Sagcal-Gironella AC, Sherwin CM, Tirona RG, Rieder MJ, Brunner HI, Vinks AA.

Clin Ther. 2011 Oct;33(10):1524-36. doi: 10.1016/j.clinthera.2011.09.015. Epub 2011 Oct 7.


Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.

Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, Larue S, Langlois N, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Carrier M, Forgie M, Wells PS, Kim RB.

Blood. 2011 Sep 15;118(11):3163-71. doi: 10.1182/blood-2011-03-345173. Epub 2011 Jul 1.


Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis.

Meyer zu Schwabedissen HE, Ware JA, Finkelstein D, Chaudhry AS, Mansell S, Leon-Ponte M, Strom SC, Zaher H, Schwarz UI, Freeman DJ, Schuetz EG, Tirona RG, Kim RB.

Hepatology. 2011 Aug;54(2):644-54. doi: 10.1002/hep.24391. Epub 2011 Jun 26.


Environmental and genetic factors affecting transport of imatinib by OATP1A2.

Eechoute K, Franke RM, Loos WJ, Scherkenbach LA, Boere I, Verweij J, Gurney H, Kim RB, Tirona RG, Mathijssen RH, Sparreboom A.

Clin Pharmacol Ther. 2011 Jun;89(6):816-20. doi: 10.1038/clpt.2011.42. Epub 2011 Apr 20.


In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna.

Cutler MJ, Urquhart BL, Velenosi TJ, Meyer Zu Schwabedissen HE, Dresser GK, Leake BF, Tirona RG, Kim RB, Freeman DJ.

J Clin Pharmacol. 2012 Apr;52(4):530-42. doi: 10.1177/0091270011400414. Epub 2011 Apr 19.


Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.

Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y, Mizuguchi K, Ho RH, Kim RB.

Pharmacogenet Genomics. 2011 Mar;21(3):103-14. doi: 10.1097/FPC.0b013e328342f5b1.


Molecular mechanisms of drug transporter regulation.

Tirona RG.

Handb Exp Pharmacol. 2011;(201):373-402. doi: 10.1007/978-3-642-14541-4_10. Review.


Determination of the Pharmacokinetics and Oral Bioavailability of Salicylamine, a Potent γ-Ketoaldehyde Scavenger, by LC/MS/MS.

Zagol-Ikapitte IA, Matafonova E, Amarnath V, Bodine CL, Boutaud O, Tirona RG, Oates JA, Roberts LJ 2nd, Davies SS.

Pharmaceutics. 2010 Mar;2(1):18-29.


Determination of the Pharmacokinetics and Oral Bioavailability of Salicylamine, a Potent γ-Ketoaldehyde Scavenger, by LC/MS/MS.

Zagol-Ikapitte I, Matafonova E, Amarnath V, Bodine CL, Boutaud O, Tirona RG, Oates JA, Roberts Ii LJ, Davies SS.

Pharmaceutics. 2010 Feb 1;2(1):18-29.


Human skeletal muscle drug transporters determine local exposure and toxicity of statins.

Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG.

Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25.


The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs.

Urquhart BL, Gregor JC, Chande N, Knauer MJ, Tirona RG, Kim RB.

Am J Physiol Gastrointest Liver Physiol. 2010 Feb;298(2):G248-54. doi: 10.1152/ajpgi.00224.2009. Epub 2009 Sep 17.


Identification, expression, and functional characterization of full-length and splice variants of murine organic anion transporting polypeptide 1b2.

Meyer Zu Schwabedissen HE, Ware JA, Tirona RG, Kim RB.

Mol Pharm. 2009 Nov-Dec;6(6):1790-7. doi: 10.1021/mp900030w.


Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer.

Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB.

Cancer Res. 2008 Nov 15;68(22):9338-47. doi: 10.1158/0008-5472.CAN-08-0265.


Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin.

Zaher H, Meyer zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, Palandra J, Stock JL, Kim RB, Ware JA.

Mol Pharmacol. 2008 Aug;74(2):320-9. doi: 10.1124/mol.108.046458. Epub 2008 Apr 15.


Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.

Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, Dresser GK, Kim RB.

Pharmacogenet Genomics. 2008 May;18(5):439-48. doi: 10.1097/FPC.0b013e3282f974dc.


A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor.

Healan-Greenberg C, Waring JF, Kempf DJ, Blomme EA, Tirona RG, Kim RB.

Drug Metab Dispos. 2008 Mar;36(3):500-7. Epub 2007 Dec 20.


Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension.

Barr FE, Tirona RG, Taylor MB, Rice G, Arnold J, Cunningham G, Smith HA, Campbell A, Canter JA, Christian KG, Drinkwater DC, Scholl F, Kavanaugh-McHugh A, Summar ML.

J Thorac Cardiovasc Surg. 2007 Aug;134(2):319-26.


Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.

Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, Bailey DG, Stein CM, Kim RB.

Pharmacogenet Genomics. 2007 Aug;17(8):647-56.


A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression.

Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB.

Mol Endocrinol. 2007 Aug;21(8):1769-80. Epub 2007 May 22.


Intestinal drug transporter expression and the impact of grapefruit juice in humans.

Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB.

Clin Pharmacol Ther. 2007 Mar;81(3):362-70. Epub 2007 Jan 10.


Supplemental Content

Loading ...
Support Center